SCHEMBL4568295

SCHEMBL4568295

Fc1cc2cc(-c3cccnc3)[nH]c2cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.58
CYP11B1 P15538 2/20 0.44
CYP11B2 P19099 1/20 0.44
NPY5R Q15761 6/20 0.42
TDO2 P48775 1/20 0.41
CYP2A6 P11509 3/20 0.40
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
CLK2 P49760 1/20 0.40
CLK3 P49761 1/20 0.40
DYRK1A Q13627 1/20 0.40
HPGD P15428 1/20 0.40
STAT1 P42224 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568273 0.83 CYP19A1 (0.58) CYP19A1CYP11B1CYP11B2NPY5RTDO2
SCHEMBL4568283 0.83 CYP19A1 (0.58) CYP19A1CYP11B1CYP11B2NPY5RCYP2A6
SCHEMBL4568264 0.82 ALDH1A1 (0.58) CYP19A1KDM4ENPC1ALDH1A1MAPT
SCHEMBL4568294 0.81 CYP19A1 (0.58) CYP19A1CYP11B1CYP11B2NPY5RTDO2
SCHEMBL4568260 0.80 CYP19A1 (0.55) CYP19A1CYP11B1CYP11B2NPY5RKDM4E
SCHEMBL4568298 0.80 CYP19A1 (0.55) CYP19A1CYP11B1CYP11B2NPY5RKDM4E
SCHEMBL4568286 0.79 CYP19A1 (0.53) CYP19A1CYP11B1CYP11B2NPY5RTDO2
SCHEMBL1605712 0.78 CYP19A1 (0.68) CYP19A1CYP11B1CYP11B2NPY5RTDO2
SCHEMBL1605273 0.78 CYP19A1 (0.68) CYP19A1NPY5RCYP2A6KDM4ENPC1
SCHEMBL1606556 0.78 CYP19A1 (0.68) CYP19A1CYP11B1CYP11B2TDO2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R CYP19A1 1262/4885CYP11B1 314/4885CYP11B2 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.